trial · primary record
Pembrolizumab
Metastatic Melanoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 78 |
| Primary completion | 2031-09-01 |
| Primary endpoint | Response rate in treatment refractory disease |
| Registry ID | NCT05155033 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:05.798Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05155033
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pembrolizumab · approval
- Pembrolizumab · compound